NEW YORK (GenomeWeb News) – Synthetic biology firm Intrexon has filed to raise up to $125 million in an initial public offering.

The Germantown, Md.-based firm has not yet determined a price range on its shares, and it didn't disclose in its Form S-1 filed with the US Securities Exchange on Tuesday how many shares it plans to offer. JP Morgan and Barclays will be joint book-running managers on the offering.

Intrexon plans to list on the New York Stock Exchange under ticker symbol "XON".

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: The sea anemone is sequenced, a team describes a CRISPR/Cas9-based approach to label specific sites in the genome, and more. 

In a short video, CNN introduces viewers to a fecal transplant poop donor and explains how the treatments are made.

Researchers are testing the use of transgenically altered diamondback moths as an alternative to pesticides in controlling the bugs.

Two recent papers published in Science and Nature Medicine describe work that may result in a universal vaccine for the flu.

Oct
29
Sponsored by
Lucigen

This webinar will focus on a range of research and clinical applications enabled by improvements in mate pair technology for whole genome sequencing.